Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Vodis Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Vodis Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vodis Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Vodis Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Vodis Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Vodis Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Vodis Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Vodis Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Vodis Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Vodis Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Vodis Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Vodis Pharmaceuticals's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Vodis Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 12.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Mark Lotz, CPA, CA., BBA, is an Interim Chief Financial Officer and Director at Ascent Industries Corp. since April 26, 2019. Mr. Lotz has been Chief Financial Officer of Handa Mining Corporation since November 1, 2018 and its Interim Chief Executive Officer since March 27, 2019. Mr. Lotz has been Chief Financial Officer of Candente Gold Corporation since October 2018 and has been Director since February 2019. He has been the Chief Financial Officer of Vodis Pharmaceuticals Inc. since October 11, 2016. Mr. Lotz served as the Chief Financial Officer of TrackX Holdings Inc., the Canadian parent of a U.S. since May 26, 2016 until May 30, 2017 and Prophecy Coal. He has Senior Management experience in the mining, manufacturing and digital media sectors. His public company experience is extensive, including Candente Copper Corp., Handa Mining and Specialty Liquid Transportation Corp. He is a senior executive with extensive experience in public companies, tax and consulting. He served as the Chief Executive Officer and Chief Financial Officer in the brokerage industry. He regularly consults with legal firms acting as an expert witness on matters of securities regulation and litigation. He is a Chartered Professional Accountant practicing publicly through his firm Lotz CPA Inc. Having qualified in 1994, he has a wealth of experience in business, tax and consulting. He has been Director of Vodis Pharmaceuticcals Inc. December 12, 2017. He has been Independent Director at PreveCeutical Medical Inc. since June 21, 2019. Mr. Lotz is a businessman and provides management consulting and corporate finance services to public and private companies. He has numerous years of experience with reporting issuers, and currently serves as a director of Golden Raven Resources Ltd., Logan Resources Ltd., Teal Valley Health Inc. (formerly Radiant Health Care Inc.), and Golden Lake Exploration Inc.
Insufficient data for Mark to compare compensation growth.
Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Vodis Pharmaceuticals board of directors is about average.
Board of Directors
Member of Advisory Committee
Member of Board of Advisors
Member of Board of Advisors
Member of Board of Advisors
Member of Board of Advisors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Does Market Volatility Impact Vodis Pharmaceuticals Inc.'s (CNSX:VP) Share Price?
Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Beta is worth considering, but it's also important to consider whether Vodis Pharmaceuticals is growing earnings and revenue. … What this means for you: Since Vodis Pharmaceuticals has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.
Do Insiders Own Shares In Vodis Pharmaceuticals Inc. (CNSX:VP)?
As Charlie Munger said 'Show me the incentive and I will show you the outcome.' Vodis Pharmaceuticals is not a large company by global standards. … Check out our latest analysis for Vodis Pharmaceuticals CNSX:VP Ownership Summary, June 26th 2019 What Does The Lack Of Institutional Ownership Tell Us About Vodis Pharmaceuticals? … Insider Ownership Of Vodis Pharmaceuticals The definition of company insiders can be subjective, and does vary between jurisdictions.
Vodis Pharmaceuticals Inc. (CNSX:VP) Insiders Have Been Selling
So shareholders might well want to know whether insiders have been buying or selling shares in Vodis Pharmaceuticals Inc. … Check out our latest analysis for Vodis Pharmaceuticals The Last 12 Months Of Insider Transactions At Vodis Pharmaceuticals The , Ivan Miliovski, made the biggest insider sale in the last 12 months. … Vodis Pharmaceuticals insiders didn't buy any shares over the last year.
Investors Who Bought Vodis Pharmaceuticals (CNSX:VP) Shares Three Years Ago Are Now Down 72%
It seems likely some shareholders believe that Vodis Pharmaceuticals will significantly advance the business plan before too long. … Vodis Pharmaceuticals has already given some investors a taste of the bitter losses that high risk investing can cause. … But with the share price diving 34% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed.
What Kind Of Shareholder Owns Most Vodis Pharmaceuticals Inc. (CNSX:VP) Stock?
The big shareholder groups in Vodis Pharmaceuticals Inc. … With a market capitalization of CA$6.8m, Vodis Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Vodis Pharmaceuticals
Need To Know: Vodis Pharmaceuticals Inc. (CNSX:VP) Insiders Have Been Selling Shares
We don't think shareholders should simply follow insider transactions. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.'? … Vodis Pharmaceuticals Insider Transactions Over The Last Year.
Are Vodis Pharmaceuticals Inc's (CNSX:VP) Interest Costs Too High?
Investors are always looking for growth in small-cap stocks like Vodis Pharmaceuticals Inc (CNSX:VP), with a market cap of CA$7.79m. … However, an important fact which most ignore is: how financially healthy is the business? … Companies operating in the Pharmaceuticals industry,
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.